According to the latest report published by Credence Research, Inc. “Endocrine Testing Market – Growth, Future Prospects and Competitive Analysis, 2017-2025,” the global endocrine testing market was valued at US$ 7,359.4 Mn in 2016, and is expected to reach US$ 14,758.6 Mn by 2025, expanding at a CAGR of 7.9% from 2017 to 2025.
Browse the full report Endocrine Testing Market – Growth, Future Prospects and Competitive Analysis, 2017–2025 report at http://www.credenceresearch.com/report/endocrine-testing-market
The endocrine systems is a setup of glands that produce and secrete hormones, vital for regulating metabolism, sexual development, body growth and other vital functions. Endocrine testing assists in determining the functioning of the endocrine glands through assessment of hormonal levels. The global endocrine testing market is driven by increasing incidence of hormonal imbalances in individuals across all age groups. Such increase in disease incidence has resulted in development of advanced diagnostic technologies thus increasing the demand for sophisticated testing methods. However, it is anticipated that significant costs involved in development of advanced testing techniques may hold back rapid commercialization of these technologies in the market, thereby restrain the market growth.
Among the various test types used in endocrine diagnostics, insulin testing and thyroid stimulating hormone test will account for the largest market share throughout the forecast period. High incidence of hyper- and hypothyroidism and increasing prevalence of diabetes are the key drivers of these segments. Additionally, being chronic in nature, these diseases demand periodic monitoring through testing methods, and at higher frequencies. This fact will ensure the dominance of these segments during the forecast period.
Based on the type of disorders, the endocrine testing market is segmented into adrenal disorders, calcium problems, glucose (islet cells) disorders, male and female gonadal problems, heart disorders, hypertensive disorders, thyroid disorders, and pituitary disorders. Among these, glucose disorders and thyroid disorders capture the highest revenue share, mainly contributed by high prevalence of these diseases. On the other hand, it is expected that diagnosis for male and female gonadal problems and heart disorders will witness the fastest growth during the forecast period on the ground of technological advancement in diagnostic techniques, enhancing their accuracy and steady rise in the incidence of the respective conditions.
On the basis of testing techniques, the global endocrine testing market is categorized into immunoassay technology, tandem mass spectrometry, sensors technology, monoclonal and polyclonal antibody technology, clinical chemistry technology and others. Tandem mass spectrometry is anticipated to witness the fastest growth during the forecast period, closely corresponded by growing accuracy of this technique and increasing application areas. The usage of endocrine testing is currently the highest in clinical laboratories and it is estimated that the same trend will continue through the forecast period.
Geographically, North America currently leads the global endocrine testing market, in terms of revenue generation. High incidence of several types of endocrine diseases, swift adoption of novel testing techniques supported by regulatory infrastructure and positive reimbursement scenario mainly contribute to the dominance of North America on the global front. Asia Pacific is observed to be the fastest progressing regional market for endocrine testing. Changes in lifestyle leading to increasing prevalence of chronic diseases and huge target population base are the prime drivers of Asia Pacific market.
To Know More About Assumptions Considered For The Study, Download Report Sample : http://www.credenceresearch.com/sample-request/58725
Some of the market players currently enjoying prominent position in the field of endocrine testing include Abbott Laboratories, AB Sciex Pte Ltd., Agilent Technologies, Inc., Biomedical Technologies (Alfa Aesar), bioMérieux SA, Bio-Rad Laboratories, Inc., DiaSorin, F. Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings, Ortho-clinical Diagnostics, Quest Technology Pte Ltd., Sysmex Corporation and Teleflex Incorporated.